PD-1- And CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

Science Translational Medicine - United States
doi 10.1126/scitranslmed.3006597
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Association for the Advancement of Science (AAAS)

Related search

Intestinal Microbiota Predict Response and Toxicities During Anti-Pd-1/Anti-Ctla-4 Immunotherapy

Pathology
Forensic MedicinePathology
2020English

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

Chimeric Antigen Receptors for T Cell Immunotherapy: Current Understanding and Future Directions

Journal of Gene Medicine
Molecular MedicineDrug DiscoveryGeneticsMolecular Biology
2012English

214. Design of Multifunctional Chimeric Antigen Receptors for T Cell Cancer Immunotherapy

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers

International Journal of Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2018English

The Other Face of Chimeric Antigen Receptors

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy

JAMA Oncology
Cancer ResearchOncology
2018English

Engineering HIV-Specific Immunity With Chimeric Antigen Receptors

AIDS Patient Care and STDs
EnvironmentalPublic HealthInfectious DiseasesOccupational Health
2016English

The Efficacy and Safety of Combination of PD-1 and CTLA-4 Inhibitors: A Meta-Analysis

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy